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Abstract
As a scientific discipline, medicine can only be advanced by experimentation. Experimentation could either validate
or refute a hypothesis. Unfortunately, today’s publication climate strongly favors publication of positive research
findings, especially with clinical trials. Experimental Hematology & Oncology (eHO) is a new open access online
journal that emphasizes preclinical, patient-oriented and translational aspects of research. The journal differentiates
from others in the field by making a deliberate effort in publishing clinical trials with “negative” results and basic
science studies with provocative findings. The focus of the peer-review mechanism for eHO will be on the
technical merit of the study and not on demanding a long list of additional experiments that hinders rapid
information dissemination.
Introduction
Medicine is moving rapidly from experience-based prac-
tice to more scientific and evidence-based endeavor.
Sharing information in real time not only makes scienti-
fic sense but also could be life-saving. There have been
instances of a number of drugs whose adverse health
effects were not made publicly available for several years
after the drug had been released onto the market. It is
our opinion that many lives could be saved by publish-
ing information such as this more widely and in a more
timely manner. For example, Gemtuzumab ozogamicin
(Mylotarg) is a calicheamicin-linked monoclonal anti-
body against CD33, approved to treat relapsed acute
myelogenous leukemia in 2000. It was voluntarily with-
drawn from the market in June 2010 due to the possibi-
lity that the drug may increase patient death and
provided no additional benefit over conventional thera-
pies [1]. However, the related study (SWOG S0106)
results have not been officially published to date.
All science that is fit to print
In the spirit of open access and rapid dissemination of
information, we are proud to launch eHO. eHO is an
open access, peer-reviewed online journal that encom-
passes all aspects of hematology and oncology with
emphasis on preclinical, patient-oriented and transla-
tional aspects of research. eHO aims to publish original
work, hypothesis, commentaries and timely reviews in
the field of hematology and oncology.
The intention of this journal is not to compete, but com-
plement the existing journals in the field. With open
access, rapid turnaround time from submission to publica-
tion and online live comments from readers, eHO will
strive to be the hub for disseminating new knowledge and
discussing controversial topics for both basic scientists and
busy clinicians in the fields of hematology and oncology.
Authors will be pleased to know that the philosophy
of this journal is to leave the judgment of the scientific
interest of the work to the readers. Instead, the editorial
and publication team [2] will focus primarily on publish-
ing original work that provides a useful contribution to
the scientific knowledge in the field, while ensuring the
highest ethical standards. Once published, articles are
freely and universally available online, meaning a higher
potential readership for the research.
For the vast majority of physicians and scientists, this
will mean that you do the science and discovery, eHO
does the publishing! The winners will be the patients
and the scientific community!
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